Volume 14, Issue 3 (9-2026)                   JoMMID 2026, 14(3): 200-210 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Bazmandegan G, Amin F, Bahrehmand F, Moinfar Z, Kamiab Z. Clinical Characteristics Associated with RT-PCR Positivity Among Patients Suspected of COVID-19 and In-Hospital Mortality Among Patients with Confirmed COVID-19. JoMMID 2026; 14 (3) :200-210
URL: http://jommid.pasteur.ac.ir/article-1-787-en.html
Department of Community Medicine, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran & Physiology-Pharmacology Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
Abstract:   (11 Views)
Introduction: Identifying clinical characteristics associated with a positive reverse transcription polymerase chain reaction (RT-PCR) result and in-hospital mortality may improve repeat-testing strategies, patient screening, and timely clinical management. This study aimed to identify factors associated with RT-PCR positivity among patients with suspected COVID-19 and factors associated with in-hospital mortality among patients with confirmed COVID-19. Methods: This retrospective observational study included 505 hospitalized patients with suspected or confirmed COVID-19 admitted to Ali-Ibn Abi-Talib Hospital, Rafsanjan, Iran, between April and July 2022. Demographic and clinical data, RT-PCR results, and outcomes were extracted from medical records. Associations with RT-PCR positivity were examined using univariable logistic regression and least absolute shrinkage and selection operator (LASSO) variable selection, followed by an unpenalized multivariable logistic regression model refitted using the selected variables. Predictive patterns and pairwise combinations associated with mortality among RT-PCR-positive patients were explored descriptively using Multifactor Dimensionality Reduction (MDR). Statistical analyses were performed using SPSS version 19, R version 3.6.3, and Python with the scikit-mdr package. Results: The mean age was 54.7 ± 20.4 years, and 52.3% of patients were male. Overall, 259 (51.3%) patients had positive RT-PCR results, among whom 30 (11.6%) died. In the refitted, post-selection model, cough (odds ratio [OR] = 1.66, 95% confidence interval [CI]: 1.13–2.44), myalgia (OR = 1.60, 95% CI: 1.08–2.38), hypertension (OR = 1.90, 95% CI: 1.05–3.51), and intubation (OR = 2.94, 95% CI: 1.41–6.33) were associated with a positive RT-PCR result, whereas cardiovascular disease and admission to the general ward or intensive care unit (ICU) (vs. isolation ward) were associated with lower odds (area under the receiver operating characteristic curve [AUC] = 0.691). In the elderly subgroup, the refitted multivariable model including dyspnea, hypertension, intubation, chronic neurological disease, and chronic kidney disease had an AUC of 0.831. MDR analysis showed that hypertension had the highest single-variable balanced accuracy for mortality (57.6%). Single-variable balanced accuracies for age ≥ 60 years (43.8%) and cough (39.1%) were below the 50% chance benchmark, suggesting unstable or poorly discriminating cross-validated classification rather than reliable effects. Conclusion: While cough, myalgia, hypertension, and intubation (a post-admission severity marker) were associated with higher odds of RT-PCR positivity, pre-existing cardiovascular disease and admission to non-isolation wards were associated with lower odds among hospitalized patients suspected of COVID-19. Among patients with confirmed COVID-19, the combination of age ≥ 60 years and cough showed the largest pairwise predictive improvement for in-hospital mortality in the MDR analysis; however, the overall predictive performance of both individual variables and variable combinations remained modest and close to the chance level. These exploratory findings may inform further evaluation of clinical assessment and repeat RT-PCR testing while emphasizing the need for externally validated multivariable prediction models for mortality risk stratification, as the present MDR analysis did not provide a validated mortality risk-stratification tool.
 
Full-Text [PDF 821 kb]   (4 Downloads)    
Type of Study: Original article | Subject: Diagnostic/screening methods and protocols
Received: 2025/09/27 | Accepted: 2026/09/10 | Published: 2026/11/16

References
1. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease 2019 (COVID-19) outbreak. J Autoimmun. 2020; 109:102433. [DOI:10.1016/j.jaut.2020.102433] [PMID]
2. Kim GU, Kim MJ, Ra SH, Lee J, Bae S, Jung J, et al. Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19. Clin Microbiol Infect. 2020; 26(7):948.e1-948.e3. [DOI:10.1016/j.cmi.2020.04.040] [PMID] [PMCID]
3. Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, Costa F, et al. COVID-19 diagnosis and management: a comprehensive review. J Intern Med. 2020; 288(2):192-206. [DOI:10.1111/joim.13091] [PMID]
4. Tanaka H, Ogata T, Shibata T, Nagai H, Takahashi Y, Kinoshita M, et al. Shorter incubation period among COVID-19 cases with the BA.1 Omicron variant. Int J Environ Res Public Health. 2022; 19(10):6330. [DOI:10.3390/ijerph19106330] [PMID] [PMCID]
5. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13):1239-42. [DOI:10.1001/jama.2020.2648] [PMID]
6. Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization and mortality among Black patients and White patients with COVID-19. N Engl J Med. 2020; 382(26):2534-43. [DOI:10.1056/NEJMsa2011686] [PMID]
7. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020; 323(16):1574-81. [DOI:10.1001/jama.2020.5394] [PMID]
8. Vardavas CI, Mathioudakis AG, Nikitara K, Stamatelopoulos K, Georgiopoulos G, Phalkey R, et al. Prognostic factors for mortality, intensive care unit and hospital admission due to SARS-CoV-2: a systematic review and meta-analysis of cohort studies in Europe. Eur Respir Rev. 2022; 31(166):220098. [DOI:10.1183/16000617.0098-2022] [PMID] [PMCID]
9. Sarri G, Liu W, Zabotka L, Freitag A, Claire R, Wangge G, et al. Prognostic factors of COVID-19: an umbrella review endorsed by the International Society for Pharmacoepidemiology. Clin Pharmacol Ther. 2023; 114(3):604-13. [DOI:10.1002/cpt.2977] [PMID] [PMCID]
10. Palacios-Moguel P, Esquivel-Pineda A, Flores-Andrade XA, Aguirre-Sanchez JS, Cruz-Arellanes NN, Sauza-Sosa JC, et al. Acute respiratory distress syndrome in patients with COVID-19 vs. non-COVID-19: clinical characteristics and outcomes in a tertiary care setting in Mexico City. BMC Pulm Med. 2023; 23(1):430. [DOI:10.1186/s12890-023-02744-6] [PMID] [PMCID]
11. Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet. 2022; 399(10332):1303-12. [DOI:10.1016/S0140-6736(22)00462-7] [PMID]
12. Smith DRM, Duval A, Zahar JR, Opatowski L, Temime L; EMAE-MESuRS Working Group on Nosocomial SARS-CoV-2 Modelling. Rapid antigen testing as a reactive response to surges in nosocomial SARS-CoV-2 outbreak risk. Nat Commun. 2022; 13(1):236. [DOI:10.1038/s41467-021-27845-w] [PMID] [PMCID]
13. Jarrom D, Elston L, Washington J, Prettyjohns M, Cann K, Myles S, et al. Effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic review. BMJ Evid Based Med. 2022; 27(1):33-45. [DOI:10.1136/bmjebm-2020-111511] [PMID]
14. World Health Organization. Diagnostic testing for SARS-CoV-2: interim guidance, 11 September 2020. Geneva: World Health Organization; 2020.
15. Sadiq Z, Rana S, Mahfoud Z, Raoof A. Systematic review and meta-analysis of chest radiograph (CXR) findings in COVID-19. Clin Imaging. 2021; 80:229-38. [DOI:10.1016/j.clinimag.2021.06.039] [PMID] [PMCID]
16. Fu F, Lou J, Xi D, Bai Y, Ma G, Zhao B, et al. Chest computed tomography findings of coronavirus disease 2019 (COVID-19) pneumonia. Eur Radiol. 2020; 30(10):5489-98. [DOI:10.1007/s00330-020-06920-8] [PMID] [PMCID]
17. Buttia C, Llanaj E, Raeisi-Dehkordi H, Kastrati L, Amiri M, Meçani R, et al. Prognostic models in COVID-19 infection that predict severity: a systematic review. Eur J Epidemiol. 2023; 38(4):355-72. [DOI:10.1007/s10654-023-00973-x] [PMID] [PMCID]
18. de Jong VM, Rousset RZ, Antonio-Villa NE, Buenen AG, Van Calster B, Bello-Chavolla OY, et al. Clinical prediction models for mortality in patients with COVID-19: external validation and individual participant data meta-analysis. BMJ. 2022; 378:e069881. [DOI:10.1136/bmj-2021-069881] [PMID]
19. Struyf T, Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Leeflang MMG, et al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19. Cochrane Database Syst Rev. 2022; 5:CD013665. [DOI:10.1002/14651858.CD013665.pub3] [PMID]
20. Parekh M, Donuru A, Balasubramanya R, Kapur S. Review of the chest CT differential diagnosis of ground-glass opacities in the COVID era. Radiology. 2020; 297(3):e289-e302. [DOI:10.1148/radiol.2020202504] [PMID] [PMCID]
21. World Health Organization. COVID-19 clinical management: living guidance, 25 January 2021. Geneva: World Health Organization; 2021.
22. Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010; 33(1):1-22. [DOI:10.18637/jss.v033.i01] [PMID]
23. R Core Team. R: a language and environment for statistical computing. Version 3.6.3. Vienna: R Foundation for Statistical Computing; 2020.
24. Ritchie MD, Hahn LW, Roodi N, Bailey LR, Dupont WD, Parl FF, et al. Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet. 2001; 69(1):138-47. [DOI:10.1086/321276] [PMID] [PMCID]
25. Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation in false-negative rate of reverse transcriptase polymerase chain reaction-based SARS-CoV-2 tests by time since exposure. Ann Intern Med. 2020; 173(4):262-7. [DOI:10.7326/M20-1495] [PMID]
26. Relan P, Motaze NV, Kothari K, Askie L, Le Polain O, Van Kerkhove MD, et al. Severity and outcomes of Omicron variant of SARS-CoV-2 compared to Delta variant and severity of Omicron sublineages: a systematic review and meta-analysis. BMJ Glob Health. 2023; 8(7):e012328. [DOI:10.1136/bmjgh-2023-012328] [PMID] [PMCID]
27. Li LQ, Huang T, Wang YQ, Wang ZP, Liang Y, Huang TB, et al. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020; 92(6):577-83. [DOI:10.1002/jmv.25757] [PMID]
28. Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, et al. Clinical features and treatment of COVID-19 patients in northeast Chongqing. J Med Virol. 2020; 92(7):797-806. [DOI:10.1002/jmv.25783] [PMID] [PMCID]
29. Talebi S, Nematshahi M, Tajabadi A, Khosrojerdi A. Comparison of clinical and epidemiological characteristics of deceased and recovered patients with COVID-19 in Sabzevar, Iran. J Mil Med. 2020; 22(6):509-16.
30. Norooznezhad AH, Najafi F, Riahi P, Moradinazar M, Shakiba E, Mostafaei S. Primary symptoms, comorbidities, and outcomes of 431 hospitalized patients with confirmative RT-PCR results for COVID-19. Am J Trop Med Hyg. 2020; 103(2):834-7. [DOI:10.4269/ajtmh.20-0512] [PMID] [PMCID]
31. Gholampour Y, Tehranineshat B, Najafi H, Farjam M, Rahimi Z, Bijani M. A study of demographic characteristics, clinical manifestations, radiologic and laboratory findings of patients hospitalized with COVID-19 in the south of Iran. J Fasa Univ Med Sci. 2020; 10(3):2456-65.
32. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020; 323(20):2052-9. [DOI:10.1001/jama.2020.6775] [PMID]
33. Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. COVID-19 and cardiovascular disease. Circulation. 2020; 141(20):1648-55. [DOI:10.1161/CIRCULATIONAHA.120.046941] [PMID]
34. Eghdampanah Foumani T, Kamyari N, Shadrvan MM, Khishvand F, Shahroud Dezful F, Kanani K, et al. Evaluation of diagnostic markers in neurological patients with COVID-19. J Med Microbiol Infect Dis. 2026; 14(1):17-23.
35. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054-62. [DOI:10.1016/S0140-6736(20)30566-3]
36. Bager P, Wohlfahrt J, Bhatt S, Stegger M, Legarth R, Møller CH, et al. Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study. Lancet Infect Dis. 2022; 22(7):967-76. [DOI:10.1016/S1473-3099(22)00154-2] [PMCID]
37. Goodarzi E, Kakavand MR, Rashidi K, Mamdohi SH, Momenabadi V, Navabi M, et al. Paraclinical characteristics of fatal and recovered COVID-19 cases: a retrospective study. J Med Microbiol Infect Dis. 2022; 10(2):80-6. [DOI:10.52547/JoMMID.10.2.80]
38. Abodunrin OR, Olagunju MT, Huang X, Wang J, Hu Z, Shen C. Regional risk factors associated with adverse outcomes of COVID-19 infection among the older adult: a systematic review and meta-analysis. J Infect Public Health. 2025; 18(2):102632. [DOI:10.1016/j.jiph.2024.102632] [PMID]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.